Vanda Pharmaceuticals (VNDA) Shares Up 5.9%

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shot up 5.9% on Friday . The stock traded as high as $18.95 and last traded at $18.70. 1,275,797 shares changed hands during trading, an increase of 126% from the average session volume of 564,946 shares. The stock had previously closed at $17.65.

Several research firms recently weighed in on VNDA. BidaskClub raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. Oppenheimer set a $27.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 15th. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. Finally, ValuEngine raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Vanda Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $21.43.

The company has a market cap of $792.97, a price-to-earnings ratio of -53.43 and a beta of 1.23.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.08. The firm had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44.00 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. The business’s quarterly revenue was up 15.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 EPS. equities research analysts expect that Vanda Pharmaceuticals Inc. will post -0.33 earnings per share for the current fiscal year.

In other news, SVP Gunther Birznieks sold 8,568 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.26, for a total value of $130,747.68. Following the transaction, the senior vice president now directly owns 118,366 shares of the company’s stock, valued at approximately $1,806,265.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now directly owns 1,031,848 shares in the company, valued at $15,787,274.40. The disclosure for this sale can be found here. Insiders have sold a total of 209,483 shares of company stock worth $3,205,205 over the last ninety days. Company insiders own 7.60% of the company’s stock.

Several large investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $308,000. Metropolitan Life Insurance Co. NY acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $221,000. Macquarie Group Ltd. lifted its stake in shares of Vanda Pharmaceuticals by 20.0% in the 4th quarter. Macquarie Group Ltd. now owns 2,268,691 shares of the biopharmaceutical company’s stock valued at $34,484,000 after purchasing an additional 378,606 shares during the period. TIAA CREF Investment Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 5.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 446,482 shares of the biopharmaceutical company’s stock valued at $6,787,000 after purchasing an additional 21,595 shares during the period. Finally, Teachers Advisors LLC lifted its stake in shares of Vanda Pharmaceuticals by 0.8% in the 4th quarter. Teachers Advisors LLC now owns 702,028 shares of the biopharmaceutical company’s stock valued at $10,671,000 after purchasing an additional 5,690 shares during the period. 89.13% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://weekherald.com/2018/02/23/vanda-pharmaceuticals-vnda-shares-up-5-9.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply